TriangleNCT03839459 · OUTCOME
Proportion of Participants With Progression to Multiple Myeloma
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 1 year
What was measured
Progression to multiple myeloma was assessed according to International Myeloma Working Group criteria during the 1 year follow up period following treatment initiation.
Analysis population: The analysis includes participants with evaluable disease progression assessment data during the 1 year follow up period.
Groups in this outcome
Denosumab
Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks
| Group | Source count |
|---|---|
| Denosumab | 17 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Denosumab | 1 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- denoms
- counts
- group Id
- OG000
- value
- 17
- units
- Participants
- description
- Progression to multiple myeloma was assessed according to International Myeloma Working Group criteria during the 1 year follow up period following treatment initiation.
- groups
- description
- Denosumab: 120mg of Denosumab will be administered subcutaneously once every 4 weeks
- id
- OG000
- title
- Denosumab
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- The analysis includes participants with evaluable disease progression assessment data during the 1 year follow up period.
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- Proportion of Participants With Progression to Multiple Myeloma
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice